ultimately monitor INR/PT for 2 weeks (particularly at 7 to 10 days) following aprepitant administration; signs/symptoms of hypersensitivity reaction. Pregnancy Considerations Adverse events were not observed in animal reproduction studies. Efficacy of hormonal contraceptive may be reduced during and for 28 days following the last aprepitant dose; alternative or additional effective methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least 1 month following the last fosaprepitant/aprepitant dose. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay sporting activities
optimal eceiving concurrent warfarin common
EmoticonEmoticon